Rama Elluru

Rama G. Elluru is currently a Senior Director at the Special Competitive Studies Project (SCSP), a non-profit, funded by Eric and Wendy Schmidt and established to make recommendations to strengthen America’s long-term competitiveness for a future where artificial intelligence (AI) and other emerging technologies reshape our national security, economy, and society.  Previous to the SCSP, she was a Director at the National Security Commission on Artificial Intelligence (NSCAI), an independent Commission established by Congress to consider the methods and means to advance the development of AI, ML, and associated technologies to address the national security and defense needs of the United States.  She was detailed to the NSCAI from the United States Patent and Trademark Office (USPTO), where she served as an Administrative Patent Judge on the Patent Trial and Appeal.  Before joining the USPTO, Rama practiced IP law for 20 years, particularly in analyzing and litigating E.E. and bio-pharma patents. She graduated from Trinity University with a B.S. in Computer Science/Philosophy and obtained a J.D. from the Washington and Lee School of Law. After law school, she received a M.S. in Biochemistry/Molecular Biology from Georgetown University.

Securing the Future of the U.S. Biopharmaceutical Industry: The Most-Favored-Nation Paradox

By Sujai Shivakumar and Anne Pritchett The Trump administration is pursuing lowering prescription drug costs primarily to end what it describes as “global freeloading” and to ensure U.S. patients pay prices comparable to those in other developed nations. The administration argues that while the United States represents less than 5 percent
Read More

Universities, Patents, and the Future of U.S. Competitiveness

By Shruti Sharma and Chris Borges Universities are among the most powerful engines of U.S. innovation, transforming federal research investments into scientific discoveries that underpin economic growth, technological leadership, and national security. Current law, via the Bayh-Dole Act, allows universities to patent inventions and license them to private companies, with royalties
Read More

How Counterfeit Drugs Threaten U.S. Health and Innovation

By Anne Pritchett According to the Department of Homeland Security, counterfeit drugs “threaten national security and public safety directly when introduced into government and critical infrastructure supply chains, and indirectly if used to generate revenue for transnational criminal organizations.” Furthermore, counterfeit drugs harm pharmaceutical innovation by eroding profitability and investor
Read More